The recently unveiled conjugate DS3610a is to start phase 1.
ApexOnco Front Page
Recent articles
After menin, the company tries again with farnesyl transferase.
The company sticks with EZH2, despite others adding EZH1 inhibition.
Questions continue to swirl as the unit mulls another oncology makeover.
Pfizer’s LILRB1 x LILRB2 bispecific is about to enter the clinic.
Five years after AbbVie pulled the plug on rova-T, DLL3 comes under the spotlight again.
But there are no hard facts, and a Ligand obligation clouds future licensing economics.
Merck turns to China for a molecule against one of biopharma’s most extensively studied antigens.